NLS Pharmaceutics Launches Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs; Company Says It Must Exercise Option By No Later Than March 31, 2024
Author: Benzinga Newsdesk | December 01, 2023 08:33am